Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
$6.83
+2.2%
$7.02
$4.07
$19.19
$422.44M1.63855,625 shs1.44 million shs
Lannett Company, Inc. stock logo
LCI
Lannett
$1.54
$0.64
$3.72
$7.38M0.9592,067 shs280,600 shs
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
$2.88
-10.3%
$4.44
$0.80
$9.62
$389.38M1.51.50 million shs3.22 million shs
OptiNose, Inc. stock logo
OPTN
OptiNose
$0.93
-4.1%
$1.48
$0.86
$2.10
$109.01M-0.24474,725 shs571,324 shs
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
$1.73
$1.38
$3.79
$117.93M1.08126,298 shs141,800 shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
+2.25%+1.79%0.00%-1.30%-63.22%
Lannett Company, Inc. stock logo
LCI
Lannett
0.00%0.00%0.00%0.00%0.00%
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
-10.28%-18.18%-32.55%-9.15%-29.41%
OptiNose, Inc. stock logo
OPTN
OptiNose
-4.38%-9.28%-38.31%-36.62%-47.72%
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
3.8803 of 5 stars
3.43.00.04.52.71.70.0
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/AN/AN/AN/AN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
4.1495 of 5 stars
4.41.00.04.12.82.50.0
OptiNose, Inc. stock logo
OPTN
OptiNose
3.1491 of 5 stars
3.53.00.04.20.02.50.6
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
2.75
Moderate Buy$14.25108.64% Upside
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
2.71
Moderate Buy$6.29118.25% Upside
OptiNose, Inc. stock logo
OPTN
OptiNose
3.00
Buy$4.00332.29% Upside
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
N/AN/AN/AN/A

Current Analyst Ratings

Latest OPTN, REPH, MRSN, LCI, and CDMO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/19/2024
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Neutral$5.00
3/18/2024
OptiNose, Inc. stock logo
OPTN
OptiNose
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
3/18/2024
OptiNose, Inc. stock logo
OPTN
OptiNose
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$3.00 ➝ $4.00
3/11/2024
OptiNose, Inc. stock logo
OPTN
OptiNose
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$5.00
3/7/2024
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$7.00
2/29/2024
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$9.00
2/29/2024
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$1.00 ➝ $5.00
2/29/2024
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$6.00
2/29/2024
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$7.00
2/29/2024
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Outperform$2.00 ➝ $7.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
$149.27M2.89$0.16 per share43.31$3.03 per share2.25
Lannett Company, Inc. stock logo
LCI
Lannett
$340.58M0.00N/AN/A($23.34) per share0.00
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
$36.85M9.48N/AN/A$0.31 per share9.29
OptiNose, Inc. stock logo
OPTN
OptiNose
$70.99M1.47N/AN/A($0.77) per share-1.20
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
$75.36M0.00N/AN/A$0.90 per share0.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
$560K-$0.17N/AN/A-8.12%-5.18%-2.16%4/29/2024 (Estimated)
Lannett Company, Inc. stock logo
LCI
Lannett
-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
-$171.67M-$1.50N/AN/AN/A-465.80%-282.36%-62.64%5/14/2024 (Estimated)
OptiNose, Inc. stock logo
OPTN
OptiNose
-$35.48M-$0.32N/AN/AN/A-50.06%N/A-33.05%5/9/2024 (Estimated)
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
-$11.37M-$0.31N/AN/AN/A-15.15%-56.66%-11.14%N/A

Latest OPTN, REPH, MRSN, LCI, and CDMO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/7/202412/31/2023
OptiNose, Inc. stock logo
OPTN
OptiNose
-$0.10-$0.09+$0.01-$0.09$19.90 million$19.87 million      
2/28/202412/31/2023
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
-$0.16-$0.16N/A-$0.16$22.59 million$10.70 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
N/AN/AN/AN/AN/A
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/AN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
N/AN/AN/AN/AN/A
OptiNose, Inc. stock logo
OPTN
OptiNose
N/AN/AN/AN/AN/A
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
0.81
1.35
0.85
Lannett Company, Inc. stock logo
LCI
Lannett
N/A
2.23
1.39
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
0.63
3.36
3.36
OptiNose, Inc. stock logo
OPTN
OptiNose
N/A
0.60
0.55
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
2.27
3.24
2.74

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
97.16%
Lannett Company, Inc. stock logo
LCI
Lannett
40.28%
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
93.92%
OptiNose, Inc. stock logo
OPTN
OptiNose
85.60%
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
62.34%

Insider Ownership

CompanyInsider Ownership
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
2.39%
Lannett Company, Inc. stock logo
LCI
Lannett
13.12%
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
12.50%
OptiNose, Inc. stock logo
OPTN
OptiNose
2.20%
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
14.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
36563.24 million61.73 millionOptionable
Lannett Company, Inc. stock logo
LCI
Lannett
81010.77 million9.35 millionOptionable
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
123121.30 million106.14 millionOptionable
OptiNose, Inc. stock logo
OPTN
OptiNose
132112.65 million110.17 millionNot Optionable
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
18556.42 million48.41 millionOptionable

OPTN, REPH, MRSN, LCI, and CDMO Headlines

SourceHeadline
Dorf Ketals Indian unit acquires veterinary pharma brandDorf Ketal's Indian unit acquires veterinary pharma brand
vccircle.com - April 10 at 10:57 PM
Fuji Pharma Co. Ltd.Fuji Pharma Co. Ltd.
wsj.com - January 30 at 3:34 PM
Aurobindo Pharma Q2 results: Net profit jumps 85% to Rs 757 croreAurobindo Pharma Q2 results: Net profit jumps 85% to Rs 757 crore
moneycontrol.com - November 22 at 10:47 PM
Retaining the human element of AI within pharma and healthcareRetaining the human element of AI within pharma and healthcare
pharmaphorum.com - November 21 at 10:06 AM
Heres what Wall Street expects from Recro Pharmas earnings reportHere's what Wall Street expects from Recro Pharma's earnings report
markets.businessinsider.com - November 7 at 12:00 PM
US supreme court halts Purdue Pharma deal that shields Sacklers from lawsuitsUS supreme court halts Purdue Pharma deal that shields Sacklers from lawsuits
theguardian.com - August 16 at 1:59 AM
Mankind Pharma share priceMankind Pharma share price
livemint.com - August 9 at 12:30 PM
What Wall Street expects from Recro Pharmas earningsWhat Wall Street expects from Recro Pharma's earnings
markets.businessinsider.com - August 9 at 7:25 AM
Mankind Pharma Ltd (MNKI)Mankind Pharma Ltd (MNKI)
investing.com - August 3 at 9:00 AM
Eversana and Amazon plan generative AI push in pharmaEversana and Amazon plan generative AI push in pharma
pharmaphorum.com - July 30 at 11:21 PM
Aurobindo Pharma Ltd.Aurobindo Pharma Ltd.
ndtv.com - July 25 at 12:39 AM
Baudax Bio acquires Maryland biotechnology firm TeraImmune; stock jumpsBaudax Bio acquires Maryland biotechnology firm TeraImmune; stock jumps
bizjournals.com - June 30 at 12:44 PM
Pharma reform: Patients can’t afford to wait. Act now.Pharma reform: Patients can’t afford to wait. Act now.
politico.eu - June 13 at 3:41 PM
Sun Pharma reports "information security incident"; isolates impacted IT assetsSun Pharma reports "information security incident"; isolates impacted IT assets
health.economictimes.indiatimes.com - March 9 at 7:26 AM
Watch: Woody Harrelson Torches Big Pharma During Hilarious Opening Monologue on SNLWatch: Woody Harrelson Torches Big Pharma During Hilarious Opening Monologue on SNL
ijr.com - March 2 at 12:30 AM
Aurobindo Pharma shares gain even as Q3 profit sinks; board declares 300% dividendAurobindo Pharma shares gain even as Q3 profit sinks; board declares 300% dividend
moneycontrol.com - February 17 at 8:43 PM
Paytm, Adani Enterprises, HUL, Sun Pharma, Lupin, Cummins, GAIL, Macrotech Developers stocks in focusPaytm, Adani Enterprises, HUL, Sun Pharma, Lupin, Cummins, GAIL, Macrotech Developers stocks in focus
financialexpress.com - December 20 at 8:48 AM
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Recro Pharma, Inc. Common Stock – SCTLPomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Recro Pharma, Inc. Common Stock – SCTL
benzinga.com - June 24 at 9:08 AM
Societal CDMO IncSocietal CDMO Inc
reuters.com - April 20 at 9:24 AM
Recro Pharma, Inc.: Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and TransformationRecro Pharma, Inc.: Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation
finanznachrichten.de - March 22 at 10:51 PM
Recro Pharma Rebrands to Societal CDMO Inc.Recro Pharma Rebrands to Societal CDMO Inc.
contractpharma.com - March 22 at 5:51 PM
Is Recro Pharma (REPH) a Worthy Investment?Is Recro Pharma (REPH) a Worthy Investment?
finance.yahoo.com - March 22 at 8:32 AM
Recap: Recro Pharma Q4 EarningsRecap: Recro Pharma Q4 Earnings
benzinga.com - March 1 at 11:55 PM
Recro Pharma Progresses Addition of Fill/Finish, Lyophilization CapabilitiesRecro Pharma Progresses Addition of Fill/Finish, Lyophilization Capabilities
contractpharma.com - February 23 at 9:51 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Avid Bioservices logo

Avid Bioservices

NASDAQ:CDMO
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services of biologics for the biotechnology and biopharmaceutical industries. The company offers various services, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
Lannett logo

Lannett

NYSE:LCI
Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.
Mersana Therapeutics logo

Mersana Therapeutics

NASDAQ:MRSN
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
OptiNose logo

OptiNose

NASDAQ:OPTN
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Recro Pharma logo

Recro Pharma

NASDAQ:REPH
Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.